# Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer

- Source: PR Newswire
- Published: 2026-10-24T12:54:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/johnson--johnson-announces-erleada-apalutamide-treatment-before-and-after-surgery-reduces-risk-of-recurrence-or-death-by-62-versus-surgery-alone-in-high-risk-prostate-cancer-302918654.html
- Canonical: https://groundlevelnews.com/story/johnson-johnson-announces-erleada-apalutamide-treatment-before-and-aft-ab4003/

New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgery Twice as many patients remained free from subsequent treatment at three years with perioperative apalutamide plus ADT compared...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._